News
03-29-2010, 07:10 AM
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that interim data from the first large-scale independent evaluation of clinical performance of Cervista® HPV HR compared to Hybrid Capture 2 (hc2), were presented at the 4th Biennial Meeting of AOGIN (Asia-Oceanic Research Organization in Genital Infection and Neoplasia) in New Delhi, India on March 26-28, 2010.
More... (http://www.news-medical.net/news/20100329/Interim-data-comparing-Cervista-HPV-HR-to-Hybrid-Capture-2-presented-at-4th-Biennial-Meeting-of-AOGIN.aspx)
More... (http://www.news-medical.net/news/20100329/Interim-data-comparing-Cervista-HPV-HR-to-Hybrid-Capture-2-presented-at-4th-Biennial-Meeting-of-AOGIN.aspx)